Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00455143 · ClinicalTrials.gov registry record · Phase 4
Cognitive Protection - Dexmedetomidine and Cognitive Reserve
A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Terminated
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
NCT00455143 is a Phase 4 study that was terminated before completion, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 27 participants.
The verdict
NCT00455143, a Phase 4 study, was terminated before completion, sponsored by Icahn School of Medicine at Mount Sinai.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a pilot study to evaluate the effect of dexmedetomidine in the prevention of delirium in non-cardiac surgical patients. The preliminary data regarding the effect of dexmedetomidine on delirium comes from a study underway at Stanford. We propose to randomize fifty patients into two different protocols, one using dexmedetomidine until PACU discharge (hip replacement) and the other using dexmedetomidine for 24 hours in a monitored setting.
Interventions
- DRUG Placebo
- DRUG Precedex (Dexmedetomidine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00455143
The ClinicalTrials.gov registry entry for NCT00455143 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00455143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00455143 about?
NCT00455143 is a clinical study titled "Cognitive Protection - Dexmedetomidine and Cognitive Reserve". This is a pilot study to evaluate the effect of dexmedetomidine in the prevention of delirium in non-cardiac surgical patients. The preliminary data regarding the effect of dexmedetomidine on delirium comes from a study underway at Stanford. We propose to randomize fifty patients into two different ...
What is the current status of trial NCT00455143?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2006-09. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00455143?
The interventions under investigation include: Placebo (DRUG), Precedex (Dexmedetomidine) (DRUG).
Who is sponsoring clinical trial NCT00455143?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.